$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

$aldx Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000156459019006997 Filed on March 08, 2019

Income Statement

Concept	2019 Q1	2018	2017 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.990M	$9.880M	$1.500M
YoY Change	58.2%	59.61%	23.97%
% of Gross Profit
Research & Development	$7.849M	$29.82M	$5.550M
YoY Change	18.92%	82.93%	60.87%
% of Gross Profit
Depreciation & Amortization	$24.24K	$71.00K	$10.00K
YoY Change	112.54%	87.6%	0.0%
% of Gross Profit
Operating Expenses	$7.849M	$29.82M	$7.050M
YoY Change	18.92%	82.93%	51.61%
Operating Profit	-$17.43M	-$39.70M
YoY Change	105.28%	76.53%
Interest Expense	$1.962K	$146.8K	$90.00K
YoY Change	-93.0%	29.39%
% of Operating Profit
Other Income/Expense, Net	$497.2K	$805.9K
YoY Change	426.97%	445.27%
Pretax Income	-$16.93M	-$38.89M	-$6.950M
YoY Change	101.67%	74.08%	49.46%
Income Tax	-$1.310M	$0.00
% Of Pretax Income
Net Earnings	-$15.62M	-$38.89M	-$6.950M
YoY Change	86.07%	74.09%	49.46%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$577.4K	-$1.793M	-$362.9K
COMMON SHARES
Basic Shares Outstanding	27.40M		19.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.12M	$93.60M	$42.90M
YoY Change	111.12%	117.93%	72.29%
Cash & Equivalents	$44.30M	$45.23M	$20.02M
Short-Term Investments	$37.83M	$46.24M	$22.90M
Other Short-Term Assets	$4.900M	$1.170M	$1.000M
YoY Change	188.24%	14.71%	400.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$87.00M	$94.77M	$43.97M
YoY Change	114.25%	115.53%	74.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$215.9K	$240.0K	$43.26K
YoY Change	26.36%	500.0%	-23.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$500.0K	$90.00K	$200.0K
YoY Change		-47.06%
Total Long-Term Assets	$1.132M	$320.0K	$209.2K
YoY Change	562.44%	60.0%	271.22%
TOTAL ASSETS
Total Short-Term Assets	$87.00M	$94.77M	$43.97M
Total Long-Term Assets	$1.132M	$320.0K	$209.2K
Total Assets	$88.13M	$95.09M	$44.17M
YoY Change	116.13%	115.28%	75.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.013M	$3.050M	$1.001M
YoY Change	147.91%	205.0%	263.4%
Accrued Expenses	$5.257M	$5.420M	$2.236M
YoY Change	189.58%	141.96%	14.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$116.3K
YoY Change		-100.0%	50.0%
Total Short-Term Liabilities	$9.492M	$8.470M	$3.354M
YoY Change	158.84%	152.84%	45.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.220M
YoY Change	-100.0%	-100.0%	-1.49%
Other Long-Term Liabilities	$200.0K
YoY Change
Total Long-Term Liabilities	$200.0K	$0.00	$1.220M
YoY Change	-81.95%	-100.0%	-1.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.492M	$8.470M	$3.354M
Total Long-Term Liabilities	$200.0K	$0.00	$1.220M
Total Liabilities	$9.648M	$8.470M	$4.574M
YoY Change	102.07%	85.34%	29.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$154.2M		-$99.64M
YoY Change	42.69%		28.9%
Common Stock	$232.6M		$139.3M
YoY Change	61.49%		40.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$78.48M	$86.62M	$39.60M
YoY Change
Total Liabilities & Shareholders Equity	$88.13M	$95.09M	$44.17M
YoY Change	116.13%	115.28%	75.38%

Cashflow Statement

Concept	2019 Q1	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$15.62M	-$38.89M	-$6.950M
YoY Change	86.07%	74.09%	49.46%
Depreciation, Depletion And Amortization	$24.24K	$71.00K	$10.00K
YoY Change	112.54%	87.6%	0.0%
Cash From Operating Activities	-$12.63M	-$29.86M	-$5.020M
YoY Change	58.8%	55.32%	28.39%
INVESTING ACTIVITIES
Capital Expenditures	$4.925K	$263.0K	-$10.00K
YoY Change	-96.46%	962.1%
Acquisitions
YoY Change
Other Investing Activities	$9.170M	-$23.07M	-$8.090M
YoY Change	85.63%	126.84%	-712.88%
Cash From Investing Activities	$9.164M	-$23.34M	-$8.110M
YoY Change	90.87%	128.83%	-714.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$807.6K	$81.84M
YoY Change	-80.27%	118.41%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	407.6K	80.53M	50.00K
YoY Change	-90.04%	115.15%	25.0%
NET CHANGE
Cash From Operating Activities	-12.63M	-29.86M	-5.020M
Cash From Investing Activities	9.164M	-23.34M	-8.110M
Cash From Financing Activities	407.6K	80.53M	50.00K
Net Change In Cash	-3.060M	27.33M	-13.08M
YoY Change	-425.45%	241.32%	412.94%
FREE CASH FLOW
Cash From Operating Activities	-$12.63M	-$29.86M	-$5.020M
Capital Expenditures	$4.925K	$263.0K	-$10.00K
Free Cash Flow	-$12.64M	-$30.12M	-$5.010M
YoY Change	56.13%	56.49%	28.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2018Q4	aldx	Cash And Money Market Funds CashAndMoneyMarketFunds	3357472
CY2017Q4	aldx	Cash And Money Market Funds CashAndMoneyMarketFunds	2023337
CY2018Q4	aldx	Cash Equivalent Reverse Repurchase Agreement CashEquivalentReverseRepurchaseAgreement	44000000
CY2017Q4	aldx	Cash Equivalent Reverse Repurchase Agreement CashEquivalentReverseRepurchaseAgreement	18000000
CY2018Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	46242220
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	22923462
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1169594
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1018967
CY2018Q4	us-gaap	Assets Current AssetsCurrent	94769286
CY2017Q4	us-gaap	Assets Current AssetsCurrent	43965766
CY2018Q4	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	86644
CY2017Q4	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	165930
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235225
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43262
CY2018Q4	us-gaap	Assets Assets	95091155
CY2017Q4	us-gaap	Assets Assets	44174958
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3051678
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1000963
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5421498
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2236465
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	116319
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8473176
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3353747
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1220192
CY2018Q4	us-gaap	Liabilities Liabilities	8473176
CY2017Q4	us-gaap	Liabilities Liabilities	4573939
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	26244
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	19138
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	225136127
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	139241635
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9224
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17831
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138535168
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99641923
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	86617979
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	39601019
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95091155
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44174958
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27395425
CY2018Q2	dei	Entity Public Float EntityPublicFloat	148308896
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19137639
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19137639
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16302568
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6185820
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-22488388
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	261252
CY2017	us-gaap	Interest Expense InterestExpense	113453
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	147799
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	21649817
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2714841
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26244435
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29823007
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	805906
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9876144
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-39699151
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26244435
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	952698
CY2018	us-gaap	Interest Expense InterestExpense	146792
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37469611
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	125292
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	7
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17960
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4144853
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	81671172
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	85573
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8607
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	4144853
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	2714841
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	59322
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20341
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	237541
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-129245
CY2018	us-gaap	Depreciation Depreciation	71003
CY2017	us-gaap	Depreciation Depreciation	37849
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	150627
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	800285
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2049582
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	725522
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3099522
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	290214
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29857131
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19222862
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	262966
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24759
CY2018	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	59731610
CY2017	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	35095083
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	36659000
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	24922000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23335576
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10197842
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81837102
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37469611
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	85573
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	125299
CY2017	aldx	Deferred Offering Costs Paid In Cash DeferredOfferingCostsPaidInCash	165930
CY2018	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1395833
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80526842
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37428980
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	27334135
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8008276
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20023337
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12015061
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47357472
CY2018	us-gaap	Interest Paid Net InterestPaidNet	88963
CY2017	us-gaap	Interest Paid Net InterestPaidNet	91633
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1172880
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk<font style="font-weight:normal;font-style:normal;"> – Financial instruments that potentially subject the Company to significant concentrations of credit risk principally consist of cash, cash equivalents and marketable securities. The Company places its cash and cash equivalents and marketable securities with financial institutions which management believes has high credit ratings. As part of its cash and investment management processes, the Company performs periodic evaluations of the credit standing of the financial institutions with whom it maintains deposits. </font></p>
CY2018	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications - <font style="font-weight:normal;font-style:normal;">Certain reclassifications have been made to prior period financial statements to conform to the current period presentation, specifically cash equivalents and reverse repurchase agreements are disclosed separately on the balance sheet for current and prior periods presented.</font></p>
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2018	aldx	Investment Maturity Period InvestmentMaturityPeriod	Three months or less
CY2018	aldx	Investment Securities Maturity Period InvestmentSecuritiesMaturityPeriod	P90D
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3822677
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3788593
CY2018Q4	us-gaap	Cash Cash	2127175
CY2018Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1230297
CY2018Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	46251444
CY2018Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	90251444
CY2017Q4	us-gaap	Cash Cash	979485
CY2017Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1043852
CY2017Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	22941293
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	40941293
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	91472517
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	41967314
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	788570
CY2018Q4	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3882313
CY2017Q4	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1327103
CY2018Q4	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	366305
CY2017Q4	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	120792
CY2018	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock is entitled to one vote
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	aldx	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00
CY2018	aldx	Net Operating Loss Carry Forwards Expiration Year NetOperatingLossCarryForwardsExpirationYear	2037
CY2018	aldx	Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear	2038
CY2018	aldx	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Assets Decrease In Valuation Allowance TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetsDecreaseInValuationAllowance	8900000
CY2018	aldx	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Decrease In Deferred Tax Assets TaxCutsAndJobsActOf2017ChangeInTaxRateDecreaseInDeferredTaxAssets	8900000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	25311547
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	16935101
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3781160
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2058771
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	164508
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	325744
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1958174
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	615490
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3146034
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2197983
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	10173
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	6409
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34371596
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22139498
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34371596
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22123292
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16206
CY2017Q4	aldx	Deferred Tax Liabilities Note Discounts DeferredTaxLiabilitiesNoteDiscounts	16206
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16206
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12200000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0683
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0537
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0381
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0300
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3151
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0151
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0020
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0111
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.3975
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.0007
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4144853
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2714841
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.00
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2246857
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1325306
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2083
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3570080
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1857645
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.87
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.38
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.24
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.18
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.10
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M23D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M8D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7909697
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5977280
CY2018Q4	us-gaap	Share Price SharePrice	8.30
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7900000
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M23D
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	40300
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.00
CY2018	aldx	Class Of Warrant Or Right Weighted Average Remaining Life Of Warrant Or Rights ClassOfWarrantOrRightWeightedAverageRemainingLifeOfWarrantOrRights	P3M18D
CY2018Q4	aldx	Class Of Warrant Or Right Number Of Shares Exercised ClassOfWarrantOrRightNumberOfSharesExercised	19700
CY2017Q4	aldx	Class Of Warrant Or Right Issued And Expired ClassOfWarrantOrRightIssuedAndExpired	0
CY2018Q1	aldx	Class Of Warrant Or Rights Expired Unexercised ClassOfWarrantOrRightsExpiredUnexercised	1324608
CY2018Q4	aldx	Indemnification Obligations Claims Outstanding IndemnificationObligationsClaimsOutstanding	0
CY2018Q4	aldx	Cash Reserve For Indemnities And Guarantees CashReserveForIndemnitiesAndGuarantees	0
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	238532
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	157682
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	465991
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	228320
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	237671
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0

Files In Submission

Name	View Source	Status
0001564590-19-006997-index-headers.html	Edgar Link	pending
0001564590-19-006997-index.html	Edgar Link	pending
0001564590-19-006997.txt	Edgar Link	pending
0001564590-19-006997-xbrl.zip	Edgar Link	pending
aldx-10k_20181231.htm	Edgar Link	pending
aldx-20181231.xml	Edgar Link	completed
aldx-20181231.xsd	Edgar Link	pending
aldx-20181231_cal.xml	Edgar Link	unprocessable
aldx-20181231_def.xml	Edgar Link	unprocessable
aldx-20181231_lab.xml	Edgar Link	unprocessable
aldx-20181231_pre.xml	Edgar Link	unprocessable
aldx-ex1035_223.htm	Edgar Link	pending
aldx-ex231_9.htm	Edgar Link	pending
aldx-ex311_8.htm	Edgar Link	pending
aldx-ex312_6.htm	Edgar Link	pending
aldx-ex321_7.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g02tsieuqjlq000001.jpg	Edgar Link	pending
g02tsieuqjlq000002.jpg	Edgar Link	pending
g02tsieuqjlq000003.jpg	Edgar Link	pending
g02tsieuqjlq000004.jpg	Edgar Link	pending
g02tsieuqjlq000005.jpg	Edgar Link	pending
g02tsieuqjlq000006.jpg	Edgar Link	pending
gwithntsufm1000001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

2019 Q1 Form 10-K Financial Statement

#000156459019006997 Filed on March 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX Aldeyra Therapeutics, Inc. Stock $aldx

2019 Q1 Form 10-K Financial Statement

#000156459019006997 Filed on March 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx